FDA approves Celgene drug for pancreatic cancer

September 7, 2013

Federal regulators have approved Celgene Inc.'s drug Abraxane to treat late-stage pancreatic cancer.

In experimental trials, the drug extended the lives of patients by a little less than two months more than those treated with the current standard drug.

Abraxane is already approved to treat and a type of lung cancer. It accounted for $155 million in revenue for Celgene in the second quarter.

Pancreatic cancer is considered especially deadly and hard to treat. It typically causes few symptoms until it has spread enough that it can't be surgically removed.

The National Cancer Institute estimates about 45,000 patients will be diagnosed and about 38,000 will die from the disease this year.

Explore further: Abraxane approved to treat advanced lung cancer

Related Stories

Abraxane approved to treat advanced lung cancer

October 14, 2012

(HealthDay)—Abraxane (paclitaxel protein-bound) has been approved by the U.S. Food and Drug Administration—in combination with the drug carboplatin—to treat advanced or spreading non-small cell lung cancer among people ...

FDA approves genetic test for lung cancer drug

May 14, 2013

The Food and Drug Administration says it approved a genetic test from Roche to help doctors identify patients who can benefit from a lung cancer drug made by Genentech.

Recommended for you

New role for an old protein: Cancer causer

September 3, 2015

A protein known to play a role in transporting the molecular contents of normal cells into and out of various intracellular compartments can also turn such cells cancerous by stimulating a key growth-control pathway.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.